Clinical Trial

The Switching Antiplatelet-9 (SWAP-9) Study

Study acronym: SWAP-9
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to compare the pharmacodynamic effects of ABCD-GENE guided vs. unguided de-escalation strategies among patients on dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-09-06; most recent amendment 2026-02-24.
Status change: Not Yet Recruiting → Recruiting 2025-02-06
Trial Details
NCT Number NCT06588595
Lead Sponsor University of Florida
Conditions Coronary Arterial Disease (CAD)
Enrollment 90 participants
Start Date 2024-11-01
Primary Completion 2026-08-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-02-25